Compare
908 Devices Inc. vs Rapid Micro Biosystems, Inc. vs EyePoint, Inc. vs Bionano Genomics, Inc.
| Latest fiscal year | 908 Devices Inc. MASS | Rapid Micro Biosystems, Inc. RPID | EyePoint, Inc. EYPT | Bionano Genomics, Inc. BNGO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $56.20M | $33.59M | $31.37M | $28.51M |
| Revenue growth (YoY) | +17.7% | +19.7% | -27.5% | -7.4% |
| Gross margin | 50.6% | n/a | n/a | 46.3% (computed) |
| Operating margin | -70.1% | -141.1% | -776.0% | -116.9% |
| Net margin | 34.7% | -140.3% | -739.4% | -92.6% |
| Net income | $19.49M | -$47.12M | -$231.96M | -$26.39M |
| EPS (Diluted) | $0.54 | -$1.05 | -$3.17 | -$4.85 |
| Operating cash flow | -$23.69M | -$31.06M | -$240.11M | -$16.34M |
| Free cash flow | -$24.64M | -$31.91M | -$243.39M | n/a |
| Cash & equivalents | $70.52M | $20.03M | $101.82M | $2.99M |
| Total assets | $190.07M | $74.85M | $364.00M | $73.58M |
| Total liabilities | $46.37M | $41.65M | $57.88M | $29.16M |
| Shareholders' equity | $143.70M | $33.21M | $306.11M | $44.42M |
| Return on year-end equity | 13.6% | -141.9% | -75.8% | -59.4% |
| Shares outstanding | 36.32M | n/a | 82.83M | 10.74M |
Revenue, most recent five fiscal years
| Fiscal year | 908 Devices Inc. | Rapid Micro Biosystems, Inc. | EyePoint, Inc. | Bionano Genomics, Inc. |
|---|---|---|---|---|
| Latest | $56.20M Ended 2025-12-31 | $33.59M Ended 2025-12-31 | $31.37M Ended 2025-12-31 | $28.51M Ended 2025-12-31 |
| 1 year earlier | $47.75M Ended 2024-12-31 | $28.05M Ended 2024-12-31 | $43.27M Ended 2024-12-31 | $30.78M Ended 2024-12-31 |
| 2 years earlier | $50.23M Ended 2023-12-31 | $22.52M Ended 2023-12-31 | $46.02M Ended 2023-12-31 | $36.12M Ended 2023-12-31 |
| 3 years earlier | $46.85M Ended 2022-12-31 | $17.13M Ended 2022-12-31 | $41.40M Ended 2022-12-31 | $27.80M Ended 2022-12-31 |
| 4 years earlier | $42.21M Ended 2021-12-31 | $23.23M Ended 2021-12-31 | $36.94M Ended 2021-12-31 | $17.98M Ended 2021-12-31 |